Last reviewed · How we verify

NCT05155085: ATLAS

A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis

Terminated Phase 2 Results posted Last updated 15 October 2024
What this trial tests

Phase 2 trial testing AK002 in Atopic Dermatitis in 131 participants. Terminated before completion.

Timeline
27 June 2022
Primary endpoint
18 December 2023
17 April 2024

Quick facts

Lead sponsorAllakos Inc.
PhasePhase 2
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment131
Start date27 June 2022
Primary completion18 December 2023
Estimated completion17 April 2024
Sites55 locations across United States, Germany

Drugs / interventions tested

Conditions studied

Sponsor

Allakos Inc. — full company profile →

Who can join

Adults 18 to 80, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

The Proportion of Subjects Who Achieve 75% Improvement on the Eczema Area and Severity Index (EASI-75) at Week 14 Primary · Baseline to Week 14

The EASI score is a tool used to measure the extent (area) and severity of atopic dermatitis with respect to erythema, excoriation, induration, and lichenification over the 4 anatomic regions of the body: lower and upper extremities, trunk, and head. The total EASI score will be in a range from 0 to 72 points (from no disease to maximum disease severity).

GroupValue95% CI
AK002 SC 300 mg (Main Study)23.0
Placebo (Main Study)18.0
Percent Change in EASI From Baseline to Week 14 Secondary · Baseline to Week 14

The EASI score is a tool used to measure the extent (area) and severity of atopic dermatitis with respect to erythema, excoriation, induration, and lichenification over the 4 anatomic regions of the body: lower and upper extremities, trunk, and head. The total EASI score will be in a range from 0 to 72 points (from no disease to maximum disease severity).

GroupValue95% CI
AK002 SC 300 mg (Main Study)-36.0± 8.7
Placebo (Main Study)-26.3± 8.7
Proportion of Subjects Achieving an IGA Score of 0 or 1 and a 2-point Improvement at Week 14 vs Baseline Secondary · Baseline to Week 14

The Investigator's Global Assessment (IGA) is a 5-point scale that provides a global clinical assessment of AD severity ranging from 0 to 4 and assesses disease severity and clinical response using a 5-point scale: 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; and 4 = severe. The score is determined by ranking the extent of erythema and papulation/infiltration. A decrease in score relates to an improvement in signs and symptoms.

GroupValue95% CI
AK002 SC 300 mg (Main Study)11.5
Placebo (Main Study)8.2
Safety and Tolerability of up to 7 Doses of Open-label AK002 in Subjects With Atopic Dermatitis in the Open-label Extension Period Secondary · Through study completion, up to 38 weeks (open-label extension period)

Adverse events were assessed throughout the open-label extension period.

Subjects with ≥1 adverse events
GroupValue95% CI
AK002 Continuing (OLE)30
Placebo Rollover (OLE)31
Subjects with ≥1 treatment-related adverse events
GroupValue95% CI
AK002 Continuing (OLE)3
Placebo Rollover (OLE)13
Subjects with an adverse event leading to study drug discontinuation
GroupValue95% CI
AK002 Continuing (OLE)2
Placebo Rollover (OLE)1
Subjects with ≥1 serious adverse events
GroupValue95% CI
AK002 Continuing (OLE)2
Placebo Rollover (OLE)0
Subjects with ≥1 treatment-related serious adverse events
GroupValue95% CI
AK002 Continuing (OLE)0
Placebo Rollover (OLE)0

Adverse events — posted to ClinicalTrials.gov

Time frame: Through study completion, up to 38 weeks (open-label extension period). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

AK002 SC 300 mg (Main Study)
Serious: 1/65 (2%)
Deaths: 0/65
Placebo (Main Study)
Serious: 3/65 (5%)
Deaths: 0/65
AK002 Continuing (OLE)
Serious: 2/55 (4%)
Deaths: 0/55
Placebo Rollover (OLE)
Serious: 0/57 (0%)
Deaths: 0/57

Serious adverse events (5 terms)

ReactionSystemAK002 SC 300 mg (Main Study)Placebo (Main Study)AK002 Continuing (OLE)Placebo Rollover (OLE)
Femur fractureInjury, poisoning and procedural complications
Eczema herpeticumInfections and infestations
Pulmonary embolismRespiratory, thoracic and mediastinal disorders
Chest painGeneral disorders
AppendicitisInfections and infestations
Other adverse events (9 terms — click to expand)

ReactionSystemAK002 SC 300 mg (Main Study)Placebo (Main Study)AK002 Continuing (OLE)Placebo Rollover (OLE)
Injection related reactionInjury, poisoning and procedural complications
Dermatitis atopicSkin and subcutaneous tissue disorders
HeadacheNervous system disorders
Injection site reactionGeneral disorders
NasopharyngitisInfections and infestations
Upper respiratory tract infectionInfections and infestations
Blood creatine phosphokinase increasedInvestigations
InfluenzaInfections and infestations
CoughRespiratory, thoracic and mediastinal disorders

Most-reported serious reactions: Femur fracture, Eczema herpeticum, Pulmonary embolism, Chest pain, Appendicitis.

Data from ClinicalTrials.gov NCT05155085 adverse events section.

Sponsor's own description

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given every 2 weeks for 7 doses, in adult subjects with moderate-to-severe AD inadequately controlled by topical treatments. Subjects who complete the randomized, double-blind, placebo-controlled treatment period may have the option to enroll in an open-label extension period and receive up to 7 doses of subcutaneous lirentelimab.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways.
    Eggel A, Pennington LF, Jardetzky TS. · · 2024 · cited 45× · PMID 39158477 · DOI 10.1111/imr.13380
  2. Human Lung Mast Cells: Therapeutic Implications in Asthma.
    Poto R, Criscuolo G, Marone G, Brightling CE, et al · · 2022 · cited 26× · PMID 36430941 · DOI 10.3390/ijms232214466
  3. Siglecs in allergy and asthma.
    Bochner BS, O'Sullivan JA, Chang AT, Youngblood BA. · · 2023 · cited 18× · PMID 35835621 · DOI 10.1016/j.mam.2022.101104
  4. Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases.
    O'Sullivan JA, Youngblood BA, Schleimer RP, Bochner BS. · · 2023 · cited 15× · PMID 37413923 · DOI 10.1016/j.smim.2023.101799
  5. From Pathogenesis to Treatment: Targeting Type-2 Inflammation in Eosinophilic Esophagitis.
    Barchi A, Mandarino FV, Yacoub MR, Albarello L, et al · · 2024 · cited 8× · PMID 39334846 · DOI 10.3390/biom14091080
  6. Role of Mast Cells in Eosinophilic Gastrointestinal Diseases.
    Khoury P, Wechsler JB. · · 2024 · cited 2× · PMID 38575226 · DOI 10.1016/j.iac.2024.01.004

Verify or expand the search:

Other trials of AK002

Trials testing the same drug.

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

Other Allakos Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05155085.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing